Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 4/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132905 | 0.82 | KRAS (0.43) | ABL1KRASJAK3BTK | |
| SCHEMBL20045414 | 0.81 | JAK3 (0.45) | JAK3BTK | |
| SCHEMBL20046512 | 0.81 | KDM5A (0.35) | KRASKDM5ABTK | |
| SCHEMBL20046113 | 0.79 | TDP2 (0.42) | KRASBTK | |
| SCHEMBL20132849 | 0.79 | ACHE (0.42) | KRASKDM5ABTK | |
| SCHEMBL20046111 | 0.79 | MAP3K5 (0.36) | KRASKDM5ABTK | |
| SCHEMBL20046110 | 0.79 | CREBBP (0.43) | KRASKDM5AJAK3BTK | |
| SCHEMBL20132843 | 0.78 | BTK (0.40) | BTKCHEK1 | |
| SCHEMBL20045443 | 0.77 | KDM5A (0.33) | KRASKDM5ABTK | |
| SCHEMBL20045472 | 0.77 | USP30 (0.45) | ABL1KRASKDM5ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | ABL1 139/4885KRAS 1/4885PRMT5 1548/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ABL1 135/4885KRAS 1/4885PRMT5 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.